Title
Efficacy/Safety Study of Nebulized IVX-0142, a Novel Antiallergic Drug, in Mild Allergic Asthma
This study is designed to evaluate the effectiveness of nebulized IVX-0142, a novel anti-allergic drug, to inhibit allergen-induced airway narrowing in patients with allergic asthma and the related increased sensitivity of the airways to other substances, as well as to investigate a possible anti-inflammatory effect of the drug in the airways.
Inclusion Criteria: Mild stable allergic asthma Positive skin-prick test to at least one common aeroallergen Positive methacholine challenge Positive allergen-induced early- and late-phase airway bronchoconstriction General good health Exclusion Criteria: Lung diseases other than mild allergic asthma History or symptoms of cardiovascular disease, significant neurologic disease, and/or clinically significant autoimmune disease Chronic use of asthma medications other than short or intermediate beta-agonists or ipratropium Use of tobacco products within one year starting study or smoking history >10 pack years If female, pregnant or lactating or have positive pregnancy test at screening
